Biocon Biologics and Regeneron settled to commercialize aflibercept-jbvf in the US, resolving patent litigation. The agreement allows Biocon to launch Yesafili in the US by the second half of 2026, or ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

Eyestem Research announced positive results from its phase 1 trial ( NCT06394232) evaluating its investigational drug product ...

Congenital ectopia lentis is a rare ocular disease characterized by the dislocation or displacement of the lens.

The partnership will integrate Ocuco’s optical software solution, Acuitas 3, with Nextech’s Ophthalmic Platform.

A study analyzed the geographic and institutional disparities in clinical trial distribution for candidates targeting the ...

VX01-DR-201, is a phase 2, multi-center, double-masked, randomized, placebo-controlled study in patients with moderate to ...

Topline data from both Phase 3 trials is expected in the second quarter of 2026, with NDA submission to follow thereafter.

Below a specific threshold, FCP exerts a protective effect, but above that threshold the protective effect becomes uncertain.

In the European Union and United Kingdom, aflibercept 8 mg (Eylea HD in the US) is currently approved for neovascular ...